BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

29731

506879

GUJTHEM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GUJARAT THEMIS BIOSYN LTD performance

Today’s low

Today’s high

₹ 273.10 ₹ 288.80
₹ 276.05

52 week low

52 week high

₹ 208.00 ₹ 330.45
₹ 276.05

Open Price

₹ 285.15

Prev. Close

₹ 284.70

Volume (Shares)

74970.00

Total traded value

₹ 206.95

Upper Circuit

₹ 341.60

Lower Circuit

₹ 227.80

info

GUJARAT THEMIS BIOSYN LTD Share Price Update

As of the latest trading session, GUJARAT THEMIS BIOSYN LTD share price is currently at ₹ 273.9, which is down by ₹ -10.80 from its previous closing. Today, the stock has fluctuated between ₹ 273.10 and ₹ 288.80. Over the past year, GUJARAT THEMIS BIOSYN LTD has achieved a return of 0.00 %. In the last month alone, the return has been 4.66 %. Read More...

GUJARAT THEMIS BIOSYN LTD fundamentals


  • Market cap (Cr)

    3,008.00

  • P/E Ratio (TTM)

    59.04

  • Beta

    -25.67

  • Book Value / share

    20.50

  • Return on equity

    33.76%

  • EPS (TTM)

    4.83

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    12.97

info icon alternate text
  • Market cap (Cr)

    2,970.90

  • P/E Ratio (TTM)

    59.04

  • Beta

    1.66

  • Book Value / share

    20.50

  • Return on equity

    33.76%

  • EPS (TTM)

    4.83

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    12.97

info icon alternate text

GUJARAT THEMIS BIOSYN LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 39.52
Operating Expense 22.36
Net Profit 12.97
Net Profit Margin (%) 32.81
Earnings Per Share (EPS) 1.19
EBITDA 19.09
Effective Tax Rate (%) 25.45
Particulars SEP 2024 (Values in Cr)
Revenue 34.72
Operating Expense 20.84
Net Profit 10.57
Net Profit Margin (%) 30.44
Earnings Per Share (EPS) 0.97
EBITDA 15.70
Effective Tax Rate (%) 25.51
Particulars JUN 2024 (Values in Cr)
Revenue 38.83
Operating Expense 21.50
Net Profit 13.24
Net Profit Margin (%) 34.09
Earnings Per Share (EPS) 1.82
EBITDA 19.08
Effective Tax Rate (%) 25.86
Particulars MAR 2024 (Values in Cr)
Revenue 42.01
Operating Expense 22.08
Net Profit 15.89
Net Profit Margin (%) 37.82
Earnings Per Share (EPS) 2.19
EBITDA 21.94
Effective Tax Rate (%) 24.15
Particulars DEC 2023 (Values in Cr)
Revenue 38.78
Operating Expense 22.16
Net Profit 13.01
Net Profit Margin (%) 33.54
Earnings Per Share (EPS) 1.79
EBITDA 18.75
Effective Tax Rate (%) 26.45
Particulars MAR 2024 (Values in Cr)
Revenue 169.82
Operating Expense 94.85
Net Profit 59.16
Net Profit Margin (%) 34.83
Earnings Per Share (EPS) 8.14
EBITDA 83.10
Effective Tax Rate (%) 25.42
Particulars MAR 2023 (Values in Cr)
Revenue 148.39
Operating Expense 77.51
Net Profit 57.97
Net Profit Margin (%) 39.06
Earnings Per Share (EPS) 39.90
EBITDA 80.22
Effective Tax Rate (%) 25.17
Particulars MAR 2022 (Values in Cr)
Revenue 114.85
Operating Expense 59.87
Net Profit 43.62
Net Profit Margin (%) 37.97
Earnings Per Share (EPS) 30.03
EBITDA 62.08
Effective Tax Rate (%) 26.10
Particulars MAR 2021 (Values in Cr)
Revenue 90.56
Operating Expense 52.94
Net Profit 30.18
Net Profit Margin (%) 33.32
Earnings Per Share (EPS) 20.77
EBITDA 43.58
Effective Tax Rate (%) 26.17
Particulars MAR 2020 (Values in Cr)
Revenue 85.12
Operating Expense 55.57
Net Profit 23.67
Net Profit Margin (%) 27.80
Earnings Per Share (EPS) 16.30
EBITDA 33.54
Effective Tax Rate (%) 24.24
Particulars MAR 2024 (Values in Cr)
Book Value / Share 27.72
ROE % 33.76
ROCE % 44.82
Total Debt to Total Equity 0.01
EBITDA Margin 48.93
Particulars MAR 2023 (Values in Cr)
Book Value / Share 102.66
ROE % 45.92
ROCE % 60.85
Total Debt to Total Equity 0.01
EBITDA Margin 54.06
Particulars MAR 2022 (Values in Cr)
Book Value / Share 71.11
ROE % 50.35
ROCE % 66.38
Total Debt to Total Equity 0.03
EBITDA Margin 54.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 48.14
ROE % 53.83
ROCE % 66.39
Total Debt to Total Equity 0.12
EBITDA Margin 48.13
Particulars MAR 2020 (Values in Cr)
Book Value / Share 29.04
ROE % 77.98
ROCE % 84.80
Total Debt to Total Equity 0.23
EBITDA Margin 39.40
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 8.15
Total Assets 221.11
Total Liabilities 221.11
Total Equity 201.37
Share Outstanding 14528702
Price to Book Ratio 14.29
Return on Assets (%) 26.75
Return on Capital (%) 29.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 9.33
Total Assets 166.32
Total Liabilities 166.32
Total Equity 149.14
Share Outstanding 14528702
Price to Book Ratio 6.69
Return on Assets (%) 34.85
Return on Capital (%) 38.87
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 12.34
Total Assets 122.50
Total Liabilities 122.50
Total Equity 103.32
Share Outstanding 14528702
Price to Book Ratio 5.73
Return on Assets (%) 35.61
Return on Capital (%) 42.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 27.63
Total Assets 88.26
Total Liabilities 88.26
Total Equity 69.94
Share Outstanding 14528702
Price to Book Ratio 4.23
Return on Assets (%) 34.19
Return on Capital (%) 41.36
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.08
Total Assets 64.07
Total Liabilities 64.07
Total Equity 42.19
Share Outstanding 14527902
Price to Book Ratio 3.35
Return on Assets (%) 36.94
Return on Capital (%) 52.17
Particulars MAR 2024 (Values in Cr)
Net Income 79.33
Cash from Operations 83.99
Cash from Investing -55.21
Cash from Financing -8.58
Net change in Cash 0.41
Free Cash Flow 158.63
Particulars MAR 2023 (Values in Cr)
Net Income 77.46
Cash from Operations 59.89
Cash from Investing -20.40
Cash from Financing -13.27
Net change in Cash 5.79
Free Cash Flow 83.60
Particulars MAR 2022 (Values in Cr)
Net Income 59.03
Cash from Operations 54.82
Cash from Investing -29.83
Cash from Financing -13.99
Net change in Cash -3.51
Free Cash Flow 68.72
Particulars MAR 2021 (Values in Cr)
Net Income 40.88
Cash from Operations 20.65
Cash from Investing -2.25
Cash from Financing -5.16
Net change in Cash 3.11
Free Cash Flow 23.71
Particulars MAR 2020 (Values in Cr)
Net Income 31.25
Cash from Operations 7.60
Cash from Investing -2.98
Cash from Financing 2.09
Net change in Cash -0.25
Free Cash Flow 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2904.45 57.61 29.41 49203.14 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

GUJARAT THEMIS BIOSYN LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
276.05 -3.03 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 288.50
  • 26 Days 268.20
  • 10 Days 288.40
  • 50 Days 220.40
  • 12 Days 287.20
  • 100 Days 150.50
  • 20 Days 278.30
  • 200 Days 56.20
283.62 PIVOT

First Support

280.08

First Resistance

288.23

Second Support

275.47

Second Resistance

291.77

Third Support

271.93

Third Resistance

296.38

RSI

52.78

ADX

33.06

MACD

19.05

Williams % R

-42.20

Commodity Channel Index (CCI)

6.39

Date

2025-04-29

Week

39463.00

Same Day

43398.00

Month

98012.00

1 Year

-25.68

3 Year

-37.29

Over 1 Month

4.66%

down

Over 1 Year

0.00%

down

Over 3 Months

16.93%

down

Over 3 Years

0.00%

down

Over 6 Months

0.00%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

GUJARAT THEMIS BIOSYN LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
26.04%
Promoter Holdings
70.86%
FII
1.91%
DII
1.17%
Promoter Shares(Pledge Percentage)
3.3%
Name Shares Category
Pharmaceutical Business Group [india] Ltd 5.124E7 (47.02%) Shareholding of Promoter and Promoter Group
Themis Medicare Limited 2.5272037E7 (23.19%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund - Quant Manufacturing Fund 1254000.0 (1.15%) Public Shareholding
Dipak Kanayalal Shah 1110000.0 (1.02%) Public Shareholding
Jayshree D Patel 529837.0 (0.49%) Shareholding of Promoter and Promoter Group
Sachin Dinesh Patel 53250.0 (0.05%) Shareholding of Promoter and Promoter Group
Reena S Patel 42000.0 (0.04%) Shareholding of Promoter and Promoter Group
Dinesh Shantilal Patel 35255.0 (0.03%) Shareholding of Promoter and Promoter Group
Nysha Rupen Choksi 22852.0 (0.02%) Shareholding of Promoter and Promoter Group
Anay Rupen Choksi 22852.0 (0.02%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

GUJARAT THEMIS BIOSYN LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
15 Jul 2024 0.25 Final 16 Jul 2024 Equity shares
22 Feb 2024 0.75 Interim 22 Feb 2024 Equity shares
01 Sep 2023 1.0 Final 02 Sep 2023 Equity shares
01 Dec 2022 4.4 Interim 02 Dec 2022 Equity shares
29 Aug 2022 4.0 Final 31 Aug 2022 Equity shares
24 Nov 2021 2.0 Interim 25 Nov 2021 Equity shares
24 Nov 2021 5.0 Special 25 Nov 2021 Equity shares
10 Sep 2020 1.65 Final 14 Sep 2020 Equity shares
Ex-Date Ex-Bonus Ratio
09 Aug 2024 09 Aug 2024 1:2
Ex-Date Old FV NEW FV Record Date
10 Oct 2023 5.0 1.0 10 Oct 2023
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
22 Feb 2024 0.75 Interim 22 Feb 2024 Equity shares
01 Sep 2023 1.0 Final 02 Sep 2023 Equity shares
01 Dec 2022 4.4 Interim 02 Dec 2022 Equity shares
29 Aug 2022 4.0 Final 31 Aug 2022 Equity shares
24 Nov 2021 2.0 Interim 25 Nov 2021 Equity shares
24 Nov 2021 5.0 Special 25 Nov 2021 Equity shares
10 Sep 2020 1.65 Final 14 Sep 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
10 Oct 2023 5.0 1.0 10 Oct 2023

GUJARAT THEMIS BIOSYN LTD Share Price

Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.

Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL.

During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics.

The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Parent organization Themis
NSE symbol GUJTHEM
Founded 1981
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Gujarat Themis Biosyn Ltd?

Answer Field

The share price of Gujarat Themis Biosyn Ltd for NSE is ₹ 273.9 and for BSE is ₹ 277.

What is the Market Cap of Gujarat Themis Biosyn Ltd?

Answer Field

The market cap of Gujarat Themis Biosyn Ltd for NSE is ₹ 30,08.00 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?

Answer Field

The 52 Week High and Low of Gujarat Themis Biosyn Ltd for NSE is ₹ 330.45 and ₹ 208.00 and for BSE is ₹ 390.00 and ₹ 192.35.

How to Buy Gujarat Themis Biosyn Ltd share?

Answer Field

You can trade in Gujarat Themis Biosyn Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Gujarat Themis Biosyn Ltd?

Answer Field

The 1 year returns on the stock has been 0.00%.

What is the Current Share Price of Gujarat Themis Biosyn Ltd?

Answer Field

Gujarat Themis Biosyn Ltd share price is for NSE ₹ 273.9 & for BSE ₹ 277 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Gujarat Themis Biosyn Ltd Share?

Answer Field

The market cap of Gujarat Themis Biosyn Ltd for NSE ₹ 30,08.00 & for BSE ₹ 0.0 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Gujarat Themis Biosyn Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Gujarat Themis Biosyn Ltd share is 59.04.

What is the PB ratio of Gujarat Themis Biosyn Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Gujarat Themis Biosyn Ltd share is 20.50.

How to Buy Gujarat Themis Biosyn Ltd Share?

Answer Field

You can trade in Gujarat Themis Biosyn Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gujarat Themis Biosyn Ltd Share on Bajaj Broking App?

Answer Field

To buy Gujarat Themis Biosyn Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gujarat Themis Biosyn Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|